These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1671652)

  • 1. Use of secondary prophylaxis against myocardial infarction in the north of England.
    Eccles M; Bradshaw C
    BMJ; 1991 Jan; 302(6768):91-2. PubMed ID: 1671652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials versus clinical practice in the secondary prevention of myocardial infarction.
    Agustí A; Arnau JM; Laporte JR
    Eur J Clin Pharmacol; 1994; 46(2):95-9. PubMed ID: 7913683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Audit of secondary prophylaxis after myocardial infarction.
    Whitford DL; Southern AJ
    BMJ; 1994 Nov; 309(6964):1268-9. PubMed ID: 7888849
    [No Abstract]   [Full Text] [Related]  

  • 4. Secondary prophylaxis against myocardial infarction.
    BMJ; 1991 Mar; 302(6777):656-7. PubMed ID: 1672826
    [No Abstract]   [Full Text] [Related]  

  • 5. An audit of discharge medication for secondary prophylaxis post-myocardial infarction.
    Richardson J; Truman C
    J Clin Pharm Ther; 1996 Dec; 21(6):413-6. PubMed ID: 9201568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborative Group.
    Second Chinese Cardiac Study (CCS-2) Collaborative Group
    J Cardiovasc Risk; 2000 Dec; 7(6):435-41. PubMed ID: 11189013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction. Towards an understanding of factors influencing clinical practice. The European Secondary Prevention Study Group.
    Woods KL; Ketley D; Lowy A; Agusti A; Hagn C; Kala R; Karatzas NB; Leizorowicz A; Reikvam A; Schilling J; Seabra-Gomes R; Vasiliauskas D; Wilhelmsen L
    Eur Heart J; 1998 Jan; 19(1):74-9. PubMed ID: 9503178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
    Vermeer NS; Bajorek BV
    J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do women with acute myocardial infarction receive the same treatment as men?
    Clarke KW; Gray D; Keating NA; Hampton JR
    BMJ; 1994 Sep; 309(6954):563-6. PubMed ID: 7916228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of local implementation of agreed guidelines for the management of patients with acute myocardial infarction.
    Badano L; Cassin M; Solinas L; Burelli C; Macor F; Zanuttini D
    G Ital Cardiol; 1999 Jan; 29(1):39-47. PubMed ID: 9987046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary prophylaxis against myocardial infarction.
    Arnau JM; Agustí A; Vidal X; Laporte JR
    BMJ; 1991 Apr; 302(6781):913. PubMed ID: 1673867
    [No Abstract]   [Full Text] [Related]  

  • 12. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
    Makam RC; Erskine N; McManus DD; Lessard D; Gore JM; Yarzebski J; Goldberg RJ
    Am J Cardiol; 2016 Dec; 118(12):1792-1797. PubMed ID: 27743577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? DARTS/MEMO Collaboration.
    MacDonald TM; Butler R; Newton RW; Morris AD
    Diabet Med; 1998 Apr; 15(4):282-9. PubMed ID: 9585392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Second prevention following myocardial infarct].
    Burkart F
    Schweiz Med Wochenschr; 1984 Jan; 114(3):104-7. PubMed ID: 6142527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction.
    Soumerai SB; McLaughlin TJ; Spiegelman D; Hertzmark E; Thibault G; Goldman L
    JAMA; 1997 Jan; 277(2):115-21. PubMed ID: 8990335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of beta-blockers after myocardial infarction.
    Turi ZG; Braunwald E
    JAMA; 1983 May; 249(18):2512-6. PubMed ID: 6133014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of age on the use of evidence-based therapies for acute myocardial infarction.
    Tran CT; Laupacis A; Mamdani MM; Tu JV
    Am Heart J; 2004 Nov; 148(5):834-41. PubMed ID: 15523314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-blockers and antithrombotics for secondary prevention after myocardial infarction.
    Ball SG
    Eur Heart J; 1998 Jan; 19(1):14-5. PubMed ID: 9503172
    [No Abstract]   [Full Text] [Related]  

  • 19. Association of increasing age with receipt of specialist care and long-term mortality in patients with non-ST elevation myocardial infarction.
    Zaman MJ; Fleetcroft R; Bachmann M; Sarev T; Stirling S; Clark A; Myint PK
    Age Ageing; 2016 Jan; 45(1):96-103. PubMed ID: 26601697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the effect on patient outcomes of appropriate and inappropriate use of beta-blockers as secondary prevention after myocardial infarction in a medicaid population.
    Fernandes AW; Madhavan SS; Amonkar MM
    Clin Ther; 2005 May; 27(5):630-45. PubMed ID: 15978313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.